CJC-1295 DAC

Evidence Anchor

BioHarmony 4.8/10

CJC-1295 with DAC sits in caution, and a step below the no-DAC form, because its one real edge, more human mechanism data and once-weekly convenience, is outweighed by a sustained action you cannot reverse, a heavier side-effect profile, an FDA-flagged immunogenicity risk, and an unresolved trial-death history. If you specifically value weekly dosing over a daily schedule, have no cardiovascular risk, and accept that a side effect lasts days, it is a defensible but second-best choice. For almost everyone the short-acting no-DAC form is better, and if evidence is the priority, tesamorelin is the stronger option, per Falutz 2007. ✅ Best for: Experienced users who place a high value on once-weekly convenience over the daily no-DAC schedule. People with no cardiovascular risk factors who can accept a sustained, non-reversible growth-hormone elevation. Older adults with lower baseline growth-hormone output, who tend to respond more, provided they monitor glucose and blood pressure. Anyone who can verify the DAC form by certificate-of-analysis molecular weight and source pharmaceutical-grade material. In practice, most of these users would be better served by the no-DAC form or tesamorelin. ❌ Avoid if: You have cardiovascular disease or risk factors, given the unresolved trial-death history and an effect that cannot be reversed. You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can promote proliferation. You are pregnant or breastfeeding. You have uncontrolled diabetes or insulin resistance, because continuous growth-hormone elevation opposes insulin more than a pulse does. You compete in tested sport, since growth-hormone-releasing factors are banned at all times under WADA S2. You want fast control over side effects, in which case the no-DAC form is the obvious choice.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.